Moderna Shares Are Trading Higher After the Company Announced the Initiation of INTerpath-009 in Combination With KEYTRUDA as Adjuvant Treatment for Patients With Resectable Stage II, IIIA or IIIB Non-small Cell Lung Cancer Who Did Not Achieve a...

Moderna股票價格上漲，因該公司宣佈以INTerpath-009與KEYTRUDA聯合治療作爲可切除的Ⅱ、ⅢA或ⅢB期非小細胞肺癌的輔助治療

Benzinga · 10/28 22:30

Moderna Shares Are Trading Higher After the Company Announced the Initiation of INTerpath-009 in Combination With KEYTRUDA as Adjuvant Treatment for Patients With Resectable Stage II, IIIA or IIIB Non-small Cell Lung Cancer Who Did Not Achieve a Pathological Complete Response After Receiving Neoadjuvant KEYTRUDA Plus Platinum-based Chemotherapy.

Moderna的股價上漲，因爲該公司宣佈啓動INTerpath-009項目，與KEYTRUDA聯合作爲輔助治療可切除的Ⅱ、ⅢA或ⅢB期非小細胞肺癌患者，這些患者在接受奧金替尼新輔助治療加鉑類化療後未達到病理完全緩解。

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。